MPS II (Hunter Syndrome)

Also known as: Hunter syndrome

What is it?

Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder caused by a deficiency of the enzyme iduronate-2-sulfatase, which is necessary for breaking down the glycosaminoglycans dermatan sulfate and heparan sulfate. The disorder results from mutations in the IDS gene. Without sufficient enzyme activity, GAGs accumulate inside lysosomes, leading to progressive cellular dysfunction and damage across multiple organ systems, particularly the skeletal, cardiovascular, respiratory, and nervous systems. MPS II presents as a spectrum ranging from severe neurologic involvement to milder attenuated disease.

How common is it?

MPS II affects approximately 1 in 100,000 to 170,000 male births worldwide. Because the condition is X-linked, it almost exclusively affects males, while females are typically carriers.

Signs & Symptoms

Symptoms usually appear in early childhood and worsen over time. Common features include: • Coarse facial features • Short stature and skeletal abnormalities • Joint stiffness and limited mobility • Enlarged liver and spleen Additional symptoms may include: • Hearing loss and recurrent ear infections • Chronic respiratory disease • Heart valve abnormalities • Behavioral problems and hyperactivity • Progressive cognitive decline in severe forms Unlike MPS I, corneal clouding is usually absent, which is an important distinguishing feature. Life expectancy depends on disease severity, with severe forms often leading to death in adolescence or early adulthood.

Causes & Inheritance

MPS II is caused by mutations in the IDS gene.

MPS II is caused by mutations in the IDS gene and is inherited in an X-linked recessive pattern. • Males with the mutation are affected • Females with one mutation are usually carriers Genetic counseling is recommended for families.

Diagnosis

Diagnosis includes: • Elevated urinary GAG levels • Enzyme assays demonstrating deficient iduronate-2-sulfatase • Genetic testing for IDS mutations Prenatal testing is possible in families with known mutations.

Treatment

Treatment focuses on slowing progression and managing symptoms. Options include: • Enzyme replacement therapy (ERT) • Supportive care addressing cardiac, respiratory, and orthopedic complications • Physical, occupational, and speech therapy ERT improves somatic symptoms but has limited effect on neurologic disease.

Disclaimer: The information provided here is for educational purposes only and should not be taken as medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment. Information sourced from reliable medical databases.

Beyond MPS II (Hunter Syndrome): The Rare Disease Landscape

While MPS II (Hunter Syndrome) has its unique clinical manifestations and genetic triggers, most Lysosomal Storage Disorders (LSDs) share a common biological mechanism: the accumulation of cellular waste due to enzyme deficiency.

In the Indian context, the diagnostic odyssey for rare genetic conditions often spans several years, involving multiple medical specialists before a definitive diagnosis is reached. Taraasha Foundation is committed to simplifying this journey through education and specialized support.

We advocate for early clinical intervention and universal newborn screening to detect these conditions before the onset of irreversible symptoms. Understanding the inheritance patterns and the biological basis of metabolic shifts is a vital step for affected families.

Through Enzyme Replacement Therapy (ERT) and emerging gene therapies, the goal of modern medicine remains the same: ensuring a sustainable quality of life and empowering patients to lead fulfilling lives despite their diagnosis.